AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Polarean Imaging (LSE:POLX) has announced the appointment of Dr. Chase Hall as its chief medical advisor. Dr. Hall, renowned for his expertise in pulmonary, critical care, and sleep medicine, is set to enhance the company's capabilities in respiratory disease imaging.
Currently serving as an associate professor at the University of Kansas Medical Center, Dr. Hall is also the associate director of the Interstitial Lung Disease and Rare Lung Disease Clinic. His work has centered on utilizing Xenon MRI to identify imaging biomarkers for respiratory conditions. Notably, he has advanced the use of Xenon MRI as a sensitive tool for assessing treatment responses and has developed rapid image acquisition protocols and automated analysis systems.
Dr. Hall’s involvement extends to the Xenon MRI clinical trials consortium, which comprises 13 research sites working to standardize imaging protocols, train new sites, and raise awareness in the field.
In his new role at Polarean, Dr. Hall will lead the company’s clinical development strategies and medical education efforts. His appointment is anticipated to significantly strengthen the company's engagement with the medical community and address key gaps in pulmonary care.
Dr. Hall will continue his clinical practice, bringing valuable insights from the frontline of pulmonary medicine to Polarean. The company’s CEO, Christopher von Jako, highlighted that Dr. Hall’s extensive expertise and advocacy for Xenon MRI technology align perfectly with Polarean’s goals. His addition is seen as a crucial step towards expanding Xenon MRI's reach to more clinical and research sites.
Dr. Hall holds a medical degree from the University of Kansas School of Medicine and has completed residency in internal medicine and fellowship training in pulmonary and critical care at Washington University School of Medicine in St. Louis. He also serves as a peer reviewer for prestigious medical journals, including Academic Radiology and The American Journal of Respiratory and Critical Care Medicine.
Dr. Hall expressed enthusiasm about joining Polarean, noting the significant unmet needs in pulmonary medicine for advanced imaging technologies that can better characterize diseases, monitor therapy responses, and guide interventions.
As of 1131 BST, Polarean Imaging’s shares had decreased by 0.35%, trading at 1.77p.
